<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="for practitioners on the use of antiviral drugs to control" exact="influenza" post="outbreaks in long-term care facilities in Canada, 2014–2015 season"/>
 <result pre="to inform health care professionals of the increased risk for" exact="influenza" post="in long-term care facilities due to a documented mismatch"/>
 <result pre="the components chosen for this season’s vaccine and currently circulating" exact="influenza" post="strains. Adjusted recommendations for the use of antiviral drugs"/>
 <result pre="strains. Adjusted recommendations for the use of antiviral drugs for" exact="influenza" post="in long-term care facilities for this season are provided."/>
 <result pre="and other health care practitioners of an increased risk of" exact="influenza" post="outbreaks in long-term care facilities (LTCF) during the 2014–2015"/>
 <result pre="influenza outbreaks in long-term care facilities (LTCF) during the 2014–2015" exact="influenza" post="season in Canada, and to provide recommendations for adjustment"/>
 <result pre="of Canada regarding early data indicating a mismatch of the" exact="influenza" post="vaccine H3N2 component to an emerging H3N2 seasonal strain."/>
 <result pre="special supplement are: Influenza A(H3N2) viruses are dominating (&amp;gt;90%) among" exact="influenza" post="detections so far in 2014–2015, and have been associated"/>
 <result pre="susceptible to the neuraminidase inhibitor (NI) drugs. The majority of" exact="influenza" post="A(H3N2) viruses (&amp;gt;95%) characterized thus far in Canada this"/>
 <result pre="key antigenic sites of the hemagglutinin (H) protein of the" exact="influenza" post="virus, and number and location of genetic differences are"/>
 <result pre="for antiviral use during LTCF outbreak control are needed while" exact="influenza" post="A(H3N2) activity shows signs of spiking in several parts"/>
 <result pre="for all staff working at the site of a declared" exact="influenza" post="A(H3N2) LTCF outbreak regardless of whether they have received"/>
 <result pre="outbreak regardless of whether they have received this year’s 2014–2015" exact="influenza" post="vaccine. C. VIROLOGICAL CONTEXT 1. Dominant influenza A(H3N2) activity"/>
 <result pre="this year’s 2014–2015 influenza vaccine. C. VIROLOGICAL CONTEXT 1. Dominant" exact="influenza" post="A(H3N2) activity early in the 2014–2015 season To date"/>
 <result pre="as of week 50, ending December 13, 2014), 4283 (96%)" exact="influenza" post="A viruses and 168 (4%) influenza B viruses have"/>
 <result pre="13, 2014), 4283 (96%) influenza A viruses and 168 (4%)" exact="influenza" post="B viruses have been detected (4). The number of"/>
 <result pre="influenza B viruses have been detected (4). The number of" exact="influenza" post="A detections in week 50 nearly doubled from the"/>
 <result pre="primarily by increased detection of A(H3N2) viruses. Of the 2011" exact="influenza" post="A viruses detected in Canada thus far with subtype"/>
 <result pre="descended from the 2009 pandemic virus, was instead the dominant" exact="influenza" post="A epidemic strain (4). 2. Evidence for antigenic drift/vaccine"/>
 <result pre="drift/vaccine mismatch among H3N2 viruses detected in Canada Of 61" exact="influenza" post="A(H3N2) viruses characterized so far this season by Canada’s"/>
 <result pre="influenza A(H3N2) viruses characterized so far this season by Canada’s" exact="influenza" post="reference laboratory, the National Microbiology Laboratory (NML), 59 (97%)"/>
 <result pre="have to be considered in declaring whether a care facility" exact="influenza" post="outbreak is facility-wide or specific to a ward/unit. When"/>
 <result pre="influenza outbreak is facility-wide or specific to a ward/unit. When" exact="influenza" post="virus is causing illness in the community, it may"/>
 <result pre="medical conditions and, in some residents, older age (21). Annual" exact="influenza" post="immunization is recommended for these individuals because of these"/>
 <result pre="high among residents. Among health care workers and other staff," exact="influenza" post="immunizations rates are more variable but generally lower than"/>
 <result pre="response associated with aging and other comorbidity. Controlling outbreaks of" exact="influenza" post="in LTCF requires a multi-faceted approach including: Surveillance for"/>
 <result pre="Control and Prevention (22). For control of an outbreak of" exact="influenza" post="among residents of a LTCF, surveillance for ILI is"/>
 <result pre="years and older, fever may not be prominent (4). Where" exact="influenza" post="is suspected, laboratory testing can confirm the diagnosis. The"/>
 <result pre="testing can confirm the diagnosis. The preferred sample for individual" exact="influenza" post="diagnosis is a nasopharyngeal specimen obtained using a flocked"/>
 <result pre="oropharyngeal secretions obtained with a throat swab are suboptimal for" exact="influenza" post="diagnosis. The preferred testing methods are, in order of"/>
 <result pre="testing methods are, in order of declining preference: RT-PCR, rapid" exact="influenza" post="diagnostic tests and viral culture. For surveillance purposes, FluWatch"/>
 <result pre="tests and viral culture. For surveillance purposes, FluWatch defines an" exact="influenza" post="outbreak on the basis of two or more cases"/>
 <result pre="a seven-day period, including at least one laboratory-confirmed case of" exact="influenza" post="(4). However, this is for surveillance purposes and the"/>
 <result pre="this is for surveillance purposes and the declaration of an" exact="influenza" post="outbreak and the enactment of control measures is at"/>
 <result pre="Officer of Health in accordance with provincial guidance. When an" exact="influenza" post="outbreak is suspected in a LTCF, this should be"/>
 <result pre="with health care and infection control practitioners, to declare an" exact="influenza" post="outbreak in a LTCF and to recommend specific interventions"/>
 <result pre="is generally accepted that antiviral drugs to treat and prevent" exact="influenza" post="in residents, together with other infection control measures, are"/>
 <result pre="other infection control measures, are important for the control of" exact="influenza" post="outbreaks in LTCF. Recommended practices with respect to antiviral"/>
 <result pre="should be administered as soon as the clinical diagnosis of" exact="influenza" post="has been made because residents of LTCF are, by"/>
 <result pre="2. Antiviral drug prophylaxis i. Residents: Upon diagnosis of an" exact="influenza" post="outbreak, all residents becoming ill should be treated (vide"/>
 <result pre="where they may have the potential to acquire or transmit" exact="influenza" post="(21) should also take prophylactic antiviral medication during the"/>
 <result pre="outbreak, regardless of whether they have received the current season’s" exact="influenza" post="vaccine. This is because, despite some vaccine protection anticipated,"/>
 <result pre="antiviral agent need to be considered for treatment doses if" exact="influenza" post="is diagnosed or considered likely. Residents or staff receiving"/>
 <result pre="current virus, another viral agent or an oseltamivir- (or zanamavir)-resistant" exact="influenza" post="virus. Expert consultation is suggested to address: the cause,"/>
 <result pre="Michel Laverdiere and Dr Danuta Skowronski: None. References REFERENCES 1.SchanzerDLSevenhuysenCWinchesterBMersereauTEstimating" exact="influenza" post="deaths in Canada, 1992–2009PLoS ONE20138e8048124312225 2.ThompsonWWShayDKWeintraubEet al.Mortality associated with"/>
 <result pre="influenza deaths in Canada, 1992–2009PLoS ONE20138e8048124312225 2.ThompsonWWShayDKWeintraubEet al.Mortality associated with" exact="influenza" post="and respiratory syncytial virus in the United StatesJAMA20032891798612517228 3.ThompsonWWShayDKWeintraubEet"/>
 <result pre="2015). 5.collab: World Health OrganizationWHO recommendations on the composition of" exact="influenza" post="virus vaccines&amp;lt;www.who.int/influenza/vaccines/virus/recommendations/en/index.html&amp;gt; (Accessed December 19, 2015). 6.AokiFYAllenUDStiverHGLaverdièreMEvansGAThe use of"/>
 <result pre="Infect Dis Med Microbiol201324Suppl C1C15C 7.BushRMBenderCASubbaraoKCoxNJFitchWMPredicting the evolution of human" exact="influenza" post="AScience19992861921510583948 8.CoxNJBenderCAThe molecular epidemiology of influenza virusesSemin Virol1995635970 9.NdifonWWingreenNSLevinSADifferential"/>
 <result pre="the evolution of human influenza AScience19992861921510583948 8.CoxNJBenderCAThe molecular epidemiology of" exact="influenza" post="virusesSemin Virol1995635970 9.NdifonWWingreenNSLevinSADifferential neutralization efficiency of hemagglutinin epitopes, antibody"/>
 <result pre="efficiency of hemagglutinin epitopes, antibody interference, and the design of" exact="influenza" post="vaccinesProc Natl Acad Sci USA20091068701619439657 10.PopovaLSmithKWestAHet al.Immunodominance of antigenic"/>
 <result pre="site B over site A of hemagglutinin of recent H3N2" exact="influenza" post="virusesPLoS One20127e4189522848649 11.KoelBFBurkeDFBestebroerTMet al.Substitutions near the receptor binding site"/>
 <result pre="near the receptor binding site determine major antigenic change during" exact="influenza" post="virus evolutionScience2013342976924264991 12.JinHZhouHLiuHet al.Two residues in the hemagglutinin of"/>
 <result pre="virus evolutionScience2013342976924264991 12.JinHZhouHLiuHet al.Two residues in the hemagglutinin of A/Fujian/411/02-like" exact="influenza" post="viruses are responsible for antigenic drift from A/Panama/2007/99Virology2005336113915866076 13.SkowronskiDMJanjuaNZDe"/>
 <result pre="drift from A/Panama/2007/99Virology2005336113915866076 13.SkowronskiDMJanjuaNZDe SerresGet al.A sentinel platform to evaluate" exact="influenza" post="vaccine effectiveness and new variant circulation, Canada 2010–11 seasonClin"/>
 <result pre="community and the householdClin Infect Dis2013561363923413420 15.SkowronskiDMJanjuaNZDe SerresGet al.Low 2012–13" exact="influenza" post="vaccine effectiveness associated with mutation in the egg-adapted H3N2"/>
 <result pre="drift in circulating virusesPLoS One20149e9215324667168 16.AndrewsNMcMenaminJDurnallHet al.Effectiveness of trivalent seasonal" exact="influenza" post="vaccine in preventing laboratory-confirmed influenza in primary care in"/>
 <result pre="16.AndrewsNMcMenaminJDurnallHet al.Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed" exact="influenza" post="in primary care in the United Kingdom: 2012/13 end"/>
 <result pre="(Accessed December 19, 2015). 20.CastillaJMartinez-BazINavascuesAet al.Vaccine effectiveness in preventing laboratory-confirmed" exact="influenza" post="in Navarre, Spain: 2013/14 mid-season analysisEuro Surveill201419pii:2070024556347 21.collab: Advisory"/>
 <result pre="Statement – National Advisory Committee on Immunization (NACI)Statement on seasonal" exact="influenza" post="vaccine for 2014–2015 22.collab: United States Centers for Disease"/>
 <result pre="United States Centers for Disease Control &amp;amp; PreventionInterim guidance for" exact="influenza" post="outbreak management in long-term care facilities(last updated December 19,"/>
</results>
